SCHEMBL1104182

SCHEMBL1104182

C=CCNC(=O)C(C)(C)CC

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 3/20 0.44
FAAH O00519 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
TSHR P16473 2/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 4/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
PKM P14618 1/20 0.35
RAB9A P51151 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17801557 0.83 TSHR (0.42) FAAHSMN1; SMN2TSHRMAPTKMT2A
SCHEMBL10818200 0.80 TSHR (0.46) FAAHSMN1; SMN2TSHRMAPTKMT2A
SCHEMBL1520811 0.79 FAAH (0.40) FAAHSMN1; SMN2TSHRMAPTKMT2A
SCHEMBL26190499 0.79 SMN1; SMN2 (0.38) FAAHSMN1; SMN2TSHRMAPTKMT2A
SCHEMBL17801624 0.79 FAAH (0.40) FAAHSMN1; SMN2TSHRMAPTKMT2A
SCHEMBL23763979 0.79 HTT (0.43) FAAHSMN1; SMN2TSHRMAPTKMT2A
SCHEMBL1520813 0.79 FAAH (0.40) FAAHSMN1; SMN2TSHRMAPTKMT2A
SCHEMBL9481967 0.77 FAAH (0.39) FAAHSMN1; SMN2TSHRMAPTKMT2A
SCHEMBL157278 0.75 SMN1; SMN2 (0.42) FAAHSMN1; SMN2TSHRMAPTKMT2A
SCHEMBL157277 0.75 SMN1; SMN2 (0.42) FAAHSMN1; SMN2TSHRMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3307738-B1 ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE UNIV MICHIGAN REGENTS (US) 2022-04-20 EP disclosed
US-20190241582-A1 Triazole ACC inhibitors and uses thereof Nimbus Apollo, Inc. 2019-08-08 US disclosed
WO-2017091617-A1 TRIAZOLE ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC (US) 2017-06-01 WO disclosed
US-8714088-B2 Lithographic printing plate precursor and lithographic printing method FUJIFILM CORPORATION (JP) 2014-05-06 US disclosed
US-8151705-B2 Method of preparing lithographic printing plate FUJIFILM CORPORATION (JP) 2012-04-10 US disclosed
US-8008379-B2 Fluorescent polymer fine particle, method for forming thereof, fluorescence detection kit, and method for detecting fluorescence FUJIFILM CORPORATION (JP) 2011-08-30 US disclosed
US-20100081771-A1 METHOD OF PREPARING LITHOGRAPHIC PRINTING PLATE FUJIFILM CORPORATION (JP) 2010-04-01 US disclosed
US-20090114108-A1 LITHOGRAPHIC PRINTING PLATE PRECURSOR AND LITHOGRAPHIC PRINTING METHOD FUJIFILM CORPORATION (JP) 2009-05-07 US disclosed
US-7507525-B2 Polymerizable composition and lithographic printing plate precursor FUJIFILM CORPORATION (JP) 2009-03-24 US disclosed
US-7279539-B2 Alkali-soluble polymer and polymerizable composition thereof FUJIFILM CORPORATION (JP) 2007-10-09 US disclosed
US-20070105990-A1 Fluorescent polymer fine particle, method for forming thereof, fluorescence detection kit, and method for detecting fluorescence FUJIFILM CORPORATION (JP) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241582-A1 Triazole ACC inhibitors and uses thereof ACACA, ACACB, ACAT1 RIPK1 2051/4885FAAH 1025/4885SMN1; SMN2 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.